SCHEMBL25752151

SCHEMBL25752151

COCCCn1nc(N)c2c(=O)n(CC(F)(F)F)ccc21

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TLR7 Q9NYK1 1/20 0.40
SCN9A Q15858 1/20 0.35
ALDH1A1 P00352 3/20 0.33
HSD17B10 Q99714 3/20 0.33
KDM4E B2RXH2 2/20 0.33
HPGD P15428 2/20 0.33
NPC1 O15118 1/20 0.33
GLA P06280 1/20 0.33
GAA P10253 1/20 0.33
RAB9A P51151 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
KDR P35968 2/20 0.32
FLT3 P36888 1/20 0.32
MAPT P10636 1/20 0.31
PIK3CD O00329 2/20 0.31
PIK3R2 O00459 2/20 0.31
PIK3CG P48736 1/20 0.31
RET P07949 1/20 0.30
MAP3K12 Q12852 2/20 0.30
LMNA P02545 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25750536 0.93 SCN9A (0.41) TLR7SCN9AALDH1A1KDRFLT3
SCHEMBL25756719 0.84 PDE5A (0.36) ALDH1A1KDM4ESMN1; SMN2MAPTLMNA
SCHEMBL25752395 0.82 CNR1 (0.33) KDM4ESMN1; SMN2MAPTLMNA
Hydrochloric Acid SCHEMBL27199341 0.81 CNR1 (0.32) KDM4ESMN1; SMN2MAPTLMNA
SCHEMBL25750514 0.79 SCN9A (0.34) SCN9AKDM4ESMN1; SMN2KDRFLT3
SCHEMBL25756536 0.75 MAP3K12 (0.34) ALDH1A1MAPTPIK3CDPIK3CGMAP3K12
SCHEMBL27199496 0.71 CNR1 (0.35) KDM4ESMN1; SMN2MAPTLMNA
SCHEMBL25757053 0.69 CNR1 (0.34) KDM4ESMN1; SMN2MAPTLMNA
Hydrochloric Acid SCHEMBL27199587 0.68 MEN1 (0.33)
SCHEMBL30860204 0.66 SCN9A (0.47) SCN9AALDH1A1HSD17B10KDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250115597-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO LTD (CN) 2025-04-10 US disclosed
US-12129250-B2 TYK2 inhibitors and compositions and methods thereof LYNK PHARMACEUTICALS CO. LTD. (CN) 2024-10-29 US disclosed
EP-4448514-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF Lynk Pharmaceuticals Co. Ltd. (CN) 2024-10-23 EP disclosed
US-20240124448-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO. LTD. (CN) 2024-04-18 US disclosed
WO-2023109954-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO. LTD. (CN) 2023-06-22 WO disclosed
WO-2023109954-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO. LTD. (CN) 2023-06-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240124448-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF TYK2, JAK2, JAK1 TLR7 1297/4885SCN9A 3861/4885ALDH1A1 4805/4885
US-20250115597-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF TYK2, JAK2, JAK1 TLR7 1297/4885SCN9A 3861/4885ALDH1A1 4805/4885
US-12129250-B2 TYK2 inhibitors and compositions and methods thereof TYK2, JAK2, JAK1 TLR7 1297/4885SCN9A 3861/4885ALDH1A1 4805/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.